Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRZI3C)

• Drug Name: R-87366 Drug Info
• Synonyms: Quinoxalin-2-ylcarbonyl-L-asparaginyl-[3(S)-amino-2(S)-hydroxy-4-phenylbutyryl]-L-proline tert-butylamide

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 464206
  CAS Number: CAS 144779-91-9
  TTD Drug ID: DMRZI3C

Molecule-Related Drug Atlas

Drug(s) Targeting Human immunodeficiency virus Protease (HIV PR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Saquinavir	DMG814N	Human immunodeficiency virus infection	1C62	Approved	[3]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[4]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[5]
Atazanavir	DMSYRBX	Human immunodeficiency virus infection	1C62	Approved	[6]
Amprenavir	DMLMXE0	Human immunodeficiency virus infection	1C62	Approved	[7]
Darunavir	DMN3GCH	Human immunodeficiency virus infection	1C62	Approved	[8]
Tipranavir	DM8HJX6	Human immunodeficiency virus infection	1C62	Approved	[9]
Fosamprenavir	DM4W9B3	Human immunodeficiency virus infection	1C62	Approved	[10]
BI 201335	DM3MXT8	Hepatitis C virus infection	1E51.1	Phase 3	[11]
BMS 650032	DMQI43G	Hepatitis C virus infection	1E51.1	Phase 2	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus Protease (HIV PR)	TT5FNQT	POL_HV1B1	Inhibitor	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008914)
• [2] In vitro and ex vivo anti-human immunodeficiency virus (HIV) activities of a new water-soluble HIV protease inhibitor, R-87366, containing (2S,3S)-3-amino-2-hydroxy-4-phenylbutanoic acid. Biol Pharm Bull. 1997 Feb;20(2):175-80.
• [3] PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study. J Med Virol. 2008 Dec;80(12):2053-63.
• [4] Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liq... J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Feb 15;877(5-6):575-80.
• [5] Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009 Apr;33(4):307-20.
• [6] Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacod... J Infect Dis. 2001 Apr 1;183(7):1126-9.
• [7] Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69(4):477-503.
• [8] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [10] Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in ... J Antimicrob Chemother. 2009 Aug;64(2):398-410.
• [11] 2011 Pipeline of Boehringer Ingelheim Pharma.
• [12] 2011 Pipeline of Bristol-Myers Squibb.